Intravenous immunoglobulin treatment of lupus nephritis*
References (40)
- et al.
New therapeutic avenues in autoinununity
Res Immunol
(1996) - et al.
Long-term follow-up of patients with lupus nephritis: a study based oh the classification of the World Health Organization
Am J Med
(1987) - et al.
Rheumatoid purpura and intravenous immunoglobulins
Revue de Medecine Interne
(1997) - et al.
Treatment of antineutroPhil cytoplasmic autoantibody-positive systemic vaseulitis and glomemlonephritis with pooled intravenous gammaglobulin
Am J Kidney Dis
(1992) - et al.
Risk factors for infection and immunoglobulin replaceem therapy in adult nephrofic syndrome
Am J Kidney Dis
(1994) - et al.
High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study
J Rheumatol
(1996) - et al.
Long term I.VIg treatment in systemic lupus erythematosus
Clin Exp Rheum
(1994) - et al.
Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia
Arthritis Rheum
(1990) - et al.
Successful treatment of refractory systemic lupus erythematosus with intravenous immunoglobulins
J Rheumatol
(1990) - et al.
Lupus refractory pleural effusion: transient response to intravenous immunoglobulins
J Rheumatol
(1991)
High-dose immunoglobulin therapy in pericarditis caused by SLE
Scand J Rheumatol
Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin
Acta Haematol
Autoimmune multiorgan involvement in elderly men is it SLE?
Clin Rheumatol
Recurrent cerebral infarction and the antiphospholipid syndrome: effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus
Ann Rheum Dis
Treatment of hemolytic anemia and severe thrombocytopenia with high-dose methylprednisolone and intravenous immunoglobulins in SLE
Scand J Rheumatol
IgG therapy in systemic lupus erythematosus: two case reports
Blut
Prolonged remission of SLE associated polyradiculoneuropathy after a single course of intravenous immunoglobulin
Scand J Rheumatol
Reversible cardiogenic shock in a patient with lupus myocarditis
J Rheumatol
Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin
Clin Exp Rheumatol
Successful treatment of early secondary myelofibrosis in SLE with IVIG
Lupus
Cited by (102)
Update on available therapies for refractory lupus nephritis
2023, Revista Colombiana de ReumatologiaEfficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature
2022, Autoimmunity ReviewsCitation Excerpt :Only one RCT [22] and one C&C [23] study were found. The rest are case reports or series [24–49], as summarized in the Fig. 1. Most of the articles not chosen dealt with the use of IVIg on patients with indications other than renal involvement.
Kidney disease
2021, Lahita’s Systemic Lupus ErythematosusRefractory lupus nephritis: When, why and how to treat
2019, Autoimmunity ReviewsCitation Excerpt :A decline in urinary protein excretion from 194 ± 208 to 114 ± 106 mg/dl after 24 months could be observed [88]. In seven patients with LN with CYC failure, addition of high dose intravenous immunoglobulin (1–6 courses of 400 mg/kg over 5 consecutive days) yielded a significant decline in proteinuria after 6 months which was accompanied by an improvement in serum albumin and a reduction in serum cholesterol [89]. Others have shown that high-dose intravenous azathioprine along with per oral azathioprine during the intervals as well as intravenous methotrexate in combination with pulse CYC may be an alternative in difficult to treat LN refractory to standard immunosuppressive measures [90,91].
Epidemiology and management of lupus nephritis
2018, Dubois' Lupus Erythematosus and Related SyndromesThe role of intravenous immunoglobulins in the treatment of rheumatoid arthritis
2015, Autoimmunity ReviewsCitation Excerpt :Because IVIG is considered a safe and effective adjunctive treatment of SLE [61,62], it may be considered for treatment in rhupus patients. The most extensive experience is with lupus nephritis in which IVIG has been shown to decrease proteinuria and improve renal function [63–66]. However, IVIG was effective in the treatment of lupus arthritis [62], neurologic manifestations [18,67–70], and hematologic autoimmune manifestations [62,67] and has also been shown in many case reports, to improve severe and resistant cutaneous lupus [71], serositis [67] and myocarditis [72,73].
- *
Supported by the Isaac and the Late Rene Razim Grant for research in autoimmunity
- 1
Lecturer, Department ofMedicine “B” and theResearch Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel
- 2
Department of Medicine “B” and the Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel
- 3
Lecturer, Department of Medicine “B” and the Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel
- 4
Professor of Medicine, Research Unit of RheumaticDiseases, Piestany, Slovakia
- 5
AttendingPhysician, Research Unit of Rheumatic Diseases, Piestany, Slovakia
- 6
Peter Poprac, MD, PhD: Attending Physician, Research Unit of Rheumatic Diseases, Piestany, Slovakia
- 7
Senior Lecturer, Rheumatology Unit, ShebaMedical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel-Aviv University, Israel
- 8
Professorof Medicine, Clinical Trial Consultant Lucca, Italy
- 9
Professor ofMedicine, Department of Medicine “B” and the Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine, Tel-Aviv University, Israel